Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients
Crossref DOI link: https://doi.org/10.1007/s00280-017-3258-0
Published Online: 2017-03-13
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mahadevan, D. http://orcid.org/0000-0002-2991-0361
Mita, Monica
Richards, Donald
McClay, Edward
Heist, Rebecca Suk
Kumar, A.
Sundararajan, S.
Naing, Aung
License valid from 2017-03-13